KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Non-Current Receivables (2022 - 2026)

TherapeuticsMD filings provide 5 years of Non-Current Receivables readings, the most recent being $13.2 million for Q1 2026.

  • On a quarterly basis, Non-Current Receivables fell 14.63% to $13.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $13.2 million, a 14.63% decrease, with the full-year FY2025 number at $13.7 million, down 14.35% from a year prior.
  • Non-Current Receivables hit $13.2 million in Q1 2026 for TherapeuticsMD, down from $13.7 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $20.3 million in Q1 2023 to a low of $13.2 million in Q1 2026.
  • Median Non-Current Receivables over the past 5 years was $16.9 million (2024), compared with a mean of $16.9 million.
  • Biggest five-year swings in Non-Current Receivables: decreased 8.73% in 2023 and later fell 14.63% in 2026.
  • TherapeuticsMD's Non-Current Receivables stood at $20.3 million in 2022, then fell by 8.73% to $18.5 million in 2023, then decreased by 13.38% to $16.0 million in 2024, then dropped by 14.35% to $13.7 million in 2025, then dropped by 3.96% to $13.2 million in 2026.
  • The last three reported values for Non-Current Receivables were $13.2 million (Q1 2026), $13.7 million (Q4 2025), and $14.3 million (Q3 2025) per Business Quant data.